tiprankstipranks
Trending News
More News >
Hemostemix Inc (TSE:HEM)
:HEM

Hemostemix (HEM) AI Stock Analysis

Compare
16 Followers

Top Page

TS

Hemostemix

(HEM)

Rating:41Neutral
Price Target:
Hemostemix's stock is primarily hindered by its poor financial performance, characterized by no revenue and high leverage. The technical analysis points to positive momentum, but valuation concerns due to negative earnings are significant. The absence of earnings call data and impactful corporate events limits further insights.

Hemostemix (HEM) vs. iShares MSCI Canada ETF (EWC)

Hemostemix Business Overview & Revenue Model

Company DescriptionHemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
How the Company Makes MoneyHemostemix makes money primarily through the development, licensing, and commercialization of its stem cell therapies. Its key revenue streams include potential licensing agreements with pharmaceutical companies, research grants, and partnerships for co-development of its therapies. Additionally, the company may generate income from milestone payments and royalties upon successful commercialization of its treatments. Hemostemix also explores opportunities for strategic collaborations to enhance its product pipeline and expand its market reach. However, as a biotechnology company in the pre-commercialization stage, it may not yet have significant revenue streams from product sales.

Hemostemix Financial Statement Overview

Summary
Hemostemix's financial health is precarious, with no revenue generation, significant losses, high leverage, and poor cash flow management. The company faces substantial financial distress, highlighting a need for strategic operational improvements and potential funding solutions.
Income Statement
5
Very Negative
Hemostemix has struggled with consistent revenue generation, as evidenced by zero revenue over the years. The company faces significant profitability challenges, with consistently negative net income and EBIT margins. There is no revenue growth, and high operating losses persist, indicating a need for strategic realignment to achieve financial sustainability.
Balance Sheet
10
Very Negative
The company's balance sheet highlights a concerning leverage situation with negative stockholder equity and a very high debt-to-equity ratio, indicating financial instability. The lack of equity and substantial liabilities present risks and limit financial flexibility. Total assets have decreased over time, exacerbating the leverage issue.
Cash Flow
15
Very Negative
Hemostemix faces significant cash flow challenges, with consistent negative operating and free cash flows, indicating reliance on external financing to maintain operations. The operating cash flow to net income ratio is unfavorable, suggesting inefficiencies in cash generation relative to earnings. The company needs to improve its cash flow management to avoid liquidity issues.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.00
Gross Profit0.00-223.00-495.00-1.10K-2.45K
EBITDA-1.98M-1.95M-4.39M-6.45M-7.47M
Net Income-2.62M-2.50M-5.24M-6.29M-7.77M
Balance Sheet
Total Assets991.86K313.76K465.35K563.05K2.32M
Cash, Cash Equivalents and Short-Term Investments705.70K155.42K135.75K219.44K257.95K
Total Debt4.94M4.32M4.13M1.48M175.00K
Total Liabilities8.20M7.68M7.23M5.85M3.42M
Stockholders Equity-7.20M-7.37M-6.77M-5.28M-1.10M
Cash Flow
Free Cash Flow-1.90M-1.42M-6.10M-3.48M-5.98M
Operating Cash Flow-1.90M-1.42M-6.10M-3.48M-5.98M
Investing Cash Flow0.000.000.00171.12K0.00
Financing Cash Flow2.45M1.44M6.02M3.27M6.21M

Hemostemix Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.14
Price Trends
50DMA
0.11
Positive
100DMA
0.13
Positive
200DMA
0.13
Positive
Market Momentum
MACD
<0.01
Positive
RSI
59.36
Neutral
STOCH
44.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:HEM, the sentiment is Positive. The current price of 0.14 is above the 20-day moving average (MA) of 0.13, above the 50-day MA of 0.11, and above the 200-day MA of 0.13, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 59.36 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:HEM.

Hemostemix Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.41B0.36-61.88%2.33%16.99%1.69%
TSKNE
42
Neutral
C$9.12M-813.02%
TSHEM
41
Neutral
C$19.84M34.47%43.45%
TSRVX
C$11.37M
TSSBM
C$15.29M
$11.07M
$32.28M-76.00%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:HEM
Hemostemix
0.14
0.08
133.33%
TSE:KNE
Kane Biotech
0.06
-0.09
-60.00%
TSE:RVX
Resverlogix
0.04
-0.02
-33.33%
TSE:SBM
Sirona Biochem
0.06
0.02
50.00%
BETRF
BetterLife Pharma
0.06
-0.02
-25.00%
PHRRF
PharmaTher Holdings Ltd
0.38
0.24
171.43%

Hemostemix Corporate Events

Hemostemix Raises $2.67M to Boost Stem Cell Research
Nov 29, 2024

Hemostemix Inc. successfully concluded its private placement, raising a total of $2,675,981 to advance its stem cell therapeutics platform. The proceeds will be used for product development, sales initiation, and general operations, highlighting the company’s commitment to its innovative medical solutions.

Hemostemix Secures $1.8M in Private Placement
Nov 5, 2024

Hemostemix has successfully closed the first tranche of its private placement, raising approximately $1.8 million to boost its stem cell therapeutics platform and other operational needs. The funding will support initiatives like the initial sales and processing of angiogenic cell precursors (ACP). Additionally, Hemostemix granted stock options to its directors and officers, furthering its strategic business goals.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 30, 2025